Halozyme Therapeutics, Inc. (HALO)
72.42
-0.05
(-0.07%)
USD |
NASDAQ |
Jan 12, 16:00
72.44
+0.02
(+0.03%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (Quarterly): 17.25M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.693B |
| Merck & Co., Inc. | 3.552B |
| AIM ImmunoTech, Inc. | 0.525M |
| Stryker Corp. | 398.00M |
| Skye Bioscience, Inc. | 9.178M |